FCMT
CPRX

Founders Capital Management (Texas)’s Catalyst Pharmaceutical CPRX Stock Holding History

Founders Capital Management (Texas)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Hold
600
– – 0.01% 279
2026
Q1 		$14.9K Hold
600
– – 0.01% 287
2025
Q4 		$14K Hold
600
– – 0.01% 281
2025
Q3 		$11.8K Buy
+600
New +$12.3K 0.01% 280

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Founders Capital Management (Texas)'s CPRX Position: Q2 2026 in Review

Founders Capital Management (Texas) held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 600 shares worth $18.9K. The position accounts for 0.01% of the portfolio, ranked #279.

Founders Capital Management (Texas) first reported a position in CPRX in Q3 2025 and has held it in 4 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Founders Capital Management (Texas) held 600 shares of Catalyst Pharmaceutical worth $18.9K as of Q2 2026.
  • Founders Capital Management (Texas) left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up 0.01% of Founders Capital Management (Texas)'s portfolio in Q2 2026, its #279 holding.
  • Founders Capital Management (Texas) first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.